Monday, November 17, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

scPharmaceuticals Reports Strong Fourth Quarter 2023 Financial Results

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

scPharmaceuticals (NASDAQ: SCPH) announced their fourth-quarter 2023 financial results on March 13, 2024. The company reported a GAAP EPS of $(0.35), which was 16.67% higher than the estimated $(0.42). This represents a 16.67% decrease from the previous year’s losses of $(0.30) per share. Additionally, scPharmaceuticals’ quarterly sales reached $6.096 million, surpassing the estimated $5.525 million by 10.33%. These strong results demonstrate a positive performance for scPharmaceuticals in the fourth quarter of 2023.

SCPH Stock Price Rises After Positive Day in the Market: Potential for Growth Ahead

On March 13, 2024, SCPH (Scpharmaceuticals Inc.) experienced a positive day in the stock market, with its share price increasing by $0.08, or 1.49%, since the market last closed.

After-hours trading saw an additional increase in SCPH’s stock price, with it rising by $0.20. This indicates that there is continued interest and demand for the stock even after the regular trading hours have ended.

Despite trading near the bottom of its 52-week range, SCPH’s recent price momentum suggests that there may be potential for growth in the future. Investors may see this as an opportunity to buy the stock at a relatively low price and potentially benefit from any future price increases.

It is important for investors to conduct their own research and analysis before making any investment decisions. The stock market can be volatile and unpredictable, so it is crucial to carefully consider all factors before buying or selling any stocks.

SCPH Stock Faces Decline in Financial Performance: What Investors Need to Know

On March 13, 2024, SCPH stock experienced a decline in its financial performance based on the data provided by CNN Money. The company’s net income for the past year was reported at -$36.84 million, showing a 31.4% decrease compared to the previous year. In the third quarter, the net income was recorded at -$15.63 million, reflecting a 10.46% decrease from the previous quarter.

Similarly, SCPH’s earnings per share (EPS) also showed a downward trend. The EPS for the past year was reported at -$1.30, indicating a 26.74% decrease from the previous year. In the third quarter, the EPS was recorded at -$0.40, showing a 10.25% decrease from the previous quarter.

Investors and stakeholders may want to closely monitor SCPH’s financial performance in the coming months to assess whether the company can reverse this downward trend and improve its profitability. It is essential for investors to conduct thorough research and consult with financial advisors before making any investment decisions related to SCPH stock.

Tags: SCPH
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Trading online

Needham Analyst Reiterates Buy Rating and 28 Price Target for Liquidia Technologies

Biopharmaceutical Stock Market Today (1)

Title Poseida Therapeutics Receives Orphan Drug Designation for PBCMAALLO1 Targeting Multiple Myeloma

From Stress Relief to Sleep Improvement: Unveiling the Latest Innovations in Vagus Nerve Stimulation Devices

Cue Health NASDAQ HLTH Q4 Earnings Report Key Highlights

Recommended

Clene Stock

A Pivotal Year for Clene’s Neurological Treatment Pipeline

3 months ago
RLI stock news

Price T Rowe Associates Inc. Cuts Holdings in Becton, Dickinson and Company as Medical Instruments Supplier Reports Strong Quarterly Earnings

2 years ago
Palantir Stock

Palantir Shares Face Mounting Pressure as Rally Shows Signs of Fatigue

3 weeks ago
Hannon Armstrong Sustainable Infrastructure Capital Stock

Hannon Armstrong Faces Critical Earnings Test

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Bristol-Myers Squibb Shares Face Setback Following Clinical Trial Halt

NuScale Power Shares Face Unrelenting Decline

Prospect Capital: A Tale of Strong Fundamentals and a Struggling Stock

Arrowhead Pharmaceuticals Faces Pivotal Week with Key FDA Decision and Earnings Report

Texas Instruments Forges Ahead with Aggressive Manufacturing Expansion

Keurig Dr Pepper’s Strategic Overhaul: A High-Stakes Transformation

Trending

Royal Gold Stock
Commodities

Royal Gold Shares Lose Their Luster Amid Market Pressures

by Dieter Jaworski
November 17, 2025
0

Royal Gold, a prominent player in the precious metals sector, faces a challenging period as its latest...

VanEck Gold Miners ETF Stock

Gold Mining ETF Approaches Critical Juncture After Stellar Rally

November 17, 2025
US Antimony Stock

UAMY Stock: A Tale of Conflicting Signals

November 17, 2025
Bristol-Myers Squibb Stock

Bristol-Myers Squibb Shares Face Setback Following Clinical Trial Halt

November 17, 2025
Nuscale Power Stock

NuScale Power Shares Face Unrelenting Decline

November 17, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Royal Gold Shares Lose Their Luster Amid Market Pressures
  • Gold Mining ETF Approaches Critical Juncture After Stellar Rally
  • UAMY Stock: A Tale of Conflicting Signals

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com